Annual General Meeting

Chair's Address & CEO Presentation

14 October 2025

Dr James Campbell, Chair

Good morning, and welcome to Prescient Therapeutics' Annual General Meeting for 2025.

It has been a transformational year for our company, marked by significant clinical progress, regulatory validation, and strategic positioning that has fundamentally strengthened Prescient's trajectory as a clinical-stage biotechnology company.

Clinical Milestones and Regulatory Recognition

The transition of PTX-100 from Phase 1b to Phase 2a represents more than just clinical advancement— it demonstrates our strategic focus and reflects confidence in the therapeutic potential of PTX-100. The U.S. FDA (FDA) has made two significant decisions relating to PTX-100, it has granted Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for relapsed or refractory mycosis fungoides. These regulatory recognitions open pathways for accelerated approval in a US$1.8 billion therapeutic market with significant unmet need.

Our Phase 1b results demonstrated a 45% overall response rate amongst all evaluable T-cell lymphoma patients, with 7 out of 7 evaluable CTCL patients receiving clinical benefit. The pharmacokinetic studies showed no drug accumulation and minimal interactions—supporting the safety profile for long-term use that will be critical for commercial success.

Most importantly, over recent months we have progressed from FDA Investigational New Drug (IND) acceptance to active patient recruitment in our phase 2a clinical study. The first patient was dosed in this study in May 2025, and we continue to add new sites with encouraging enrolment progress to date.

Financial Strength and Capital Position

We enter this AGM in a position of financial strength, having augmented a year-end cash position of $6.9 million with a successful $6.8 million Share Purchase Plan and $3 million placement in July

and August—raising nearly $10 million to support PTX-100's Phase 2a development. The strong participation in both the SPP and placement reflects shareholder confidence in our strategy and excitement for what lies ahead.

Leadership and Team Building

This year's leadership transitions have positioned Prescient for accelerated growth. James McDonnell joined as CEO in January, bringing extensive biotech and pharma networks that will prove increasingly valuable as we advance toward registration-enabling trials.

We strengthened our executive team with Dr Rebecca Tunstall as Chief Operating Officer and Dr Marissa Lim as Chief Medical Officer—seasoned professionals who enhance our drug development capabilities. The Board welcomed Melanie Farris, whose substantial Australian biotech experience adds valuable perspective to our strategy and governance capabilities.

Strategic Partnerships and Innovation Pipeline

Our collaborations with leading institutions—Yale, UPenn, Oxford, Moffitt, and Peter MacCallum Cancer Centre—continue to validate our technologies and expand our scientific networks. These partnerships are instrumental in advancing our pipeline and reinforcing our reputation as a forward-thinking innovator in oncology.

While our cell therapy platforms CellPryme and OmniCAR require limited investment during PTX-100's critical Phase 2a period, the reengineering improvements we've achieved in OmniCAR position these programs favourably for future reactivation when market conditions improve.

Looking Forward

As we progress through FY2026, Prescient has never been in a stronger position. We have a robust pipeline, meaningful regulatory engagement, a strong balance sheet, and an expert team of seasoned drug development executives.

Our immediate focus remains the successful execution of the PTX-100 Phase 2a trial—a study that could position us for accelerated regulatory pathways and potential partnership opportunities in a substantial market.

The fundamentals are in place: compelling clinical data, regulatory validation, financial resources, and an experienced team. We remain committed to creating long-term shareholder value while maintaining the highest standards of governance and execution.

Acknowledgments

On behalf of the Board, I thank our patients who participate in our trials, the clinicians and researchers who collaborate with us, and our loyal shareholders who continue to support our mission.

The team looks forward to sharing the next phase of our journey with you.

Thank you.

The CEO AGM presentation follows.

- Ends -

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor enquiries

Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100: is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas and Fast Track Designation for the treatment of adults with

relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the phase 2a part of the trial.

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward- looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward- looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance

or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

AGM CEO Presentation

October 2025

ASX: PTX

ptxtherapeutics.com

General

Disclaimer and Safe Harbour

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company. Nothing in this document should be considered financial advice. Please consult your professional investment adviser who understands your risk appetite and financial objectives before considering an investment in Prescient.

Executive Summary

PTX-100 First in Class Targeted Therapy Disrupting the RAS Pathway

Unique and First	First in class RAS disruptor through inhibition of geranylgeranyl transferase 1 preventing prenylation of RAS super family GTPases
Phase 2 Progress	Phase 2a initiated in refractory/relapsed Cutaneous T Cell Lymphoma (r/rCTCL) on the back of favourable results in the Phase 1b
Clear Pathway and Supporting Designations	Orphan Drug designation for T Cell Lymphomas and Fast Track designation in r/rCTCL
Re-rating Potential	Phase 2a study update, at the time of the first dose optimisation review

General

Company Snapshot

KEY METRICS

ASX Ticker	**PTX**
Total Issued Capital	1,051 M shares
Share Price[1]	A$0.043
Market Capitalisation[1]	**A$45 M**
Cash Position[2]	**A$12.32M**
Top 20 Own	19.5%

1. As at 10 October 2025
2. As at 30 September 2025 (4C)

Milestone Review (CY)

Achieved Milestones Provided Focus for PTX-100 Phase 2a Initiation



Board and Management Team

Experienced team of drug developers and deal makers with track record in blood cancers

Management Team

James McDonnell
CEO

Dr Rebecca Tunstall
COO

Dr Marissa Lim
Chief Medical Officer

Upaly Bahadure
Director – Clinical Affairs & Operations

Luis Malaver-Ortega, PhD
Director Research and Development

Board of Directors

Dr James Campbell
Non-Executive Chairman

Dr Allen Ebens
Non-Executive Director

Dr Ellen Feigal
Non- Executive Director

Dr Gavin Shepherd
Non-Executive Director

Melanie Farris
Non-Executive Director

Experienced gained in global companies

Bristol Myers Squibb · Telix · GSK · IPSEN · Cephalon · BeiGene · Genentech · VIFOR PHARMA · CSL · JUNO THERAPEUTICS · NOVARTIS · AMGEN

Targeted RAS therapy for cancers of unmet need
Potential application to 22% of all cancers

Our Lead Asset– PTX-100

- Addressing cancer : T-Cell Lymphoma (TCL) and identifying other indications
- Early results beyond benchmarks and existing drugs
- FDA support though designations
- US$1.8bn focus market* for TCL
- In Phase 2a for r/rCTCL (7 sites activated, 6 patients dosed as at end of September quarter)
- Potential for 2b registration study

*Global Data, 8 major markets: US, France, Germany, Italy, Spain, UK, Japan, and China

Phase 1b Sub-analysis of CTCL Patient Cohort
Response Rates, Safety and Duration are Key Drivers

	Benchmark[1]	Lymphir[2,3]	PTX-100 (Phase 1B)[4]	PTX-100 (CTCL only)[5]
Response Rate	30%	36%	45%	43%
Clinical Benefit Rate	45%	NA	64%	100%
Duration of Response	9-13 months CTCL 3-4 Months PTCL	6.5 months (CTCL)	10.7 months	12.4 months
Serious Adverse Events	<30%	36%	0%[6]	0%[6]

1. Considered a target benchmark by Prescient and its investigators, with reference to currently available therapies in r/r TCL
2. Label as per FDA.gov; Fierce Pharma; EF Hutton report
3. Approved by the FDA 8 Aug 2024
4. 11 evaluable patients
5. 7 evaluable patients
6. Serious Adverse events that were treatment related

Progressing PTX-100 Through Phase 2 with FDA IND acceptance



Multicenter clinical trial

Australia (3) USA (6)

France (3) Italy (3)

- **Phase 2a:** N=40 pts with r/r CTCL (dose optimisation)
- **Phase 2b:** N=75 pts with r/r CTCL will be treated at the recommended dose from Phase 2a
- **Involving international experts in CTCL treatment**

PTX-100 (CTCL) – Status Quo

PTX-100 (CTCL)



FDA Engagement

2023 **Orphan Drug Designation (ODD)**

2024 **Investigational New Drug (IND) acceptance**

2025 **Fast Track Designation (FTD)**

MA = Marketing Authorization

Adapted from Capuano, A. *et al; Front. In Pharmacol.*; Feb 2019

Potential for a Shortened Registration Pathway



MA = Marketing Authorization

Adapted from Capuano, A. *et al; Front. In Pharmacol.*; Feb 2019

*Global Data, 8 major markets: US, France, Germany, Italy, Spain, UK, Japan, and China

PTX-100 First in Class Targeted Therapy

Identifying PTX-100 RAS sensitive tumours to expand indications





- Potential application to 22% of cancers
- First in class enzyme inhibitor
- PTX-100 (TCL) = proof of concept
- Opportunity for significantly larger cancer markets

Approaching Milestones (CY)
Implementation Will Drive Value



Executive Summary

PTX-100 First in Class Targeted Therapy Disrupting the RAS Pathway

Unique and First	First in class RAS disruptor through inhibition of geranylgeranyl transferase 1 preventing prenylation of RAS super family GTPases
Phase 2 Progress	Phase 2a initiated in refractory/relapsed Cutaneous T Cell Lymphoma (r/rCTCL) on the back of favourable results in the Phase 1b
Clear Pathway and Supporting Designations	Orphan Drug designation for T Cell Lymphomas and Fast Track designation in r/rCTCL
Re-rating Potential	Phase 2a study update, at the time of the first dose optimisation review

General

Prescient Therapeutics

Thank you

ASX: PTX

ptxtherapeutics.com

General